{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:15:41Z","timestamp":1787786141934,"version":"build-2784847793"},"reference-count":62,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2025.0014","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T07:56:45Z","timestamp":1744358205000},"source":"Crossref","is-referenced-by-count":2,"title":["New bladder preservation strategies in urothelial carcinoma of the bladder."],"prefix":"10.3238","author":[{"given":"Axel","family":"Heidenreich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"B\u00f6hmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Bolenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Borkowetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantin","family":"Rieger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"De Santis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2025,4,18]]},"reference":[{"key":"10.3238\/arztebl.m2025.0014_ref1","unstructured":"Robert-Koch-Institut \u2013 Zentrum f\u00fcr Krebsregisterdaten. www.krebsdaten.de\/Krebs\/DE\/Content\/Krebsarten\/Harnblasenkrebs\/harnblasenkrebs_node.html (last accessed on 17 February 2025)."},{"key":"10.3238\/arztebl.m2025.0014_ref2","doi-asserted-by":"crossref","unstructured":"Jubber I, Ong S, Bukavina L, et al.: Epidemiology of bladder cancer in 2023: a systematic review of risk factors. Eur Urol 2023; 84: 176\u201390","DOI":"10.1016\/j.eururo.2023.03.029"},{"key":"10.3238\/arztebl.m2025.0014_ref3","doi-asserted-by":"crossref","unstructured":"Babjuk M, Burger M, Capoun O, et al.: European Association of Urology Guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol 2022; 81: 75\u201394","DOI":"10.1016\/j.eururo.2021.08.010"},{"key":"10.3238\/arztebl.m2025.0014_ref4","doi-asserted-by":"crossref","unstructured":"Witjes AJ, Bruins MH, Carri\u00f3n A, et al.: European Association of Urology Guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines. Eur Urol 2024; 85: 17\u201331","DOI":"10.1016\/j.eururo.2023.08.016"},{"key":"10.3238\/arztebl.m2025.0014_ref5","doi-asserted-by":"crossref","unstructured":"Powles T, Bellmunt J, Comperat E, et al.: ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma. Ann Oncol 2024; 35: 485\u201390","DOI":"10.1016\/j.annonc.2024.03.001"},{"key":"10.3238\/arztebl.m2025.0014_ref6","doi-asserted-by":"crossref","unstructured":"Xia L, Dadabhoy A, Wood EL, et al.: Pathologic and survival outcomes following radical cystectomy for \u201eprogressive\u201c and \u201ede novo\u201c muscle-invasive bladder cancer: a meta-analysis stratified by neoadjuvant chemotherapy status. Urol Oncol 2024; 42: e1\u2013e13","DOI":"10.1016\/j.urolonc.2024.04.020"},{"key":"10.3238\/arztebl.m2025.0014_ref7","doi-asserted-by":"crossref","unstructured":"Meyer A, Ghandour R, Bergman A, et al.: The natural history of clinically complete responders to neoadjuvant chemotherapy for urothelial carcinoma of the bladder. J Urol 2014; 192: 696\u2013701","DOI":"10.1016\/j.juro.2014.03.078"},{"key":"10.3238\/arztebl.m2025.0014_ref8","doi-asserted-by":"crossref","unstructured":"Necchi A, Daneshmand S, Simone G, et al.: TAR-200 in patients with bacillus Calmette-Gu\u00e9rin-unresponsive high-risk non-muscle-invasive bladder cancer: results from sunrise-1 study. J Urol 2024; 211, e1","DOI":"10.1097\/01.JU.0001015816.87470.c9.01"},{"key":"10.3238\/arztebl.m2025.0014_ref9","doi-asserted-by":"crossref","unstructured":"Racioppi M, Di Gianfrancesco L, Ragonese M, Palermo G, Sacco E, Bassi PF: ElectroMotive Drug Administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk \u201eBCG failure\u201c non muscle invasive bladder cancer: 3 years follow-up outcomes. BMC Cancer 2018; 18: 1224","DOI":"10.1186\/s12885-018-5134-7"},{"key":"10.3238\/arztebl.m2025.0014_ref10","doi-asserted-by":"crossref","unstructured":"Kastner L, Rieger C, Pfister D, Schmautz M, Storz E, Heidenreich A: HIVEC as an alternative option in non-muscle-invasive bladder cancer: experiences from a high-volume center. Urol Oncol 2024; 42: e19\u2013e26","DOI":"10.1016\/j.urolonc.2024.01.300"},{"key":"10.3238\/arztebl.m2025.0014_ref11","doi-asserted-by":"crossref","unstructured":"Pignot G, Baboudjian M, Lebacle C, et al.: Efficacy of hyperthermic intravesical chemotherapy (HIVEC) in patients with non-muscle invasive bladder cancer after BCG failure. World J Urol 2023; 41: 3195\u2013203","DOI":"10.1007\/s00345-023-04332-z"},{"key":"10.3238\/arztebl.m2025.0014_ref12","doi-asserted-by":"crossref","unstructured":"Pijpers OM, Hendricksen K, Mostafid H, et al.: Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer. Urol Oncol 2022; 40: e13\u2013e20","DOI":"10.1016\/j.urolonc.2021.07.019"},{"key":"10.3238\/arztebl.m2025.0014_ref13","doi-asserted-by":"crossref","unstructured":"Hurle R, Contieri R, Casale P, et al.: Midterm follow-up (3 years) confirms and extends short-term results of intravesical gemcitabine as bladder-preserving treatment for non-muscle-invasive bladder cancer after BCG failure. Urol Oncol 2021; 39: e7\u2013e13","DOI":"10.1016\/j.urolonc.2020.09.017"},{"key":"10.3238\/arztebl.m2025.0014_ref14","doi-asserted-by":"crossref","unstructured":"Prasanna T, Craft P, Balasingam G, Haxhimolla H, Pranavan GF: Intravesical gemcitabine versus intravesical bacillus Calmette-Gu\u00e9rin for the treatment of non-muscle invasive bladder cancer: an evaluation of efficacy and toxicity. Front Oncol 2017; 7: 260","DOI":"10.3389\/fonc.2017.00260"},{"key":"10.3238\/arztebl.m2025.0014_ref15","doi-asserted-by":"crossref","unstructured":"Di Lorenzo G, Perdon\u00e0 S, Damiano R, et al.: Gemcitabine versus bacille Calmette-Gu\u00e9rin after initial bacille Calmette-Gu\u00e9rin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial. Cancer 2010; 116: 1893\u2013900","DOI":"10.1002\/cncr.24914"},{"key":"10.3238\/arztebl.m2025.0014_ref16","doi-asserted-by":"crossref","unstructured":"Steinberg RL, Thomas LJ, Brooks N, et al.: Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer. J Urol 2020; 203: 902\u20139","DOI":"10.1097\/JU.0000000000000688"},{"key":"10.3238\/arztebl.m2025.0014_ref17","doi-asserted-by":"crossref","unstructured":"Chevuru PT, McElree IM, Mott SL, Steinberg RL, O\u2018Donnell MA, Packiam VT: Long-term follow-up of sequential intravesical gemcitabine and docetaxel salvage therapy for non-muscle invasive bladder cancer. Urol Oncol 2023; 41: e1\u2013e7","DOI":"10.1016\/j.urolonc.2022.10.030"},{"key":"10.3238\/arztebl.m2025.0014_ref18","doi-asserted-by":"crossref","unstructured":"Yim K, Melnick K, Mott SL, et al.: Sequential intravesical gemcitabine\/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy. Urol Oncol 2023; 41: e1\u2013e7","DOI":"10.1016\/j.urolonc.2023.06.018"},{"key":"10.3238\/arztebl.m2025.0014_ref19","doi-asserted-by":"crossref","unstructured":"Garneau CA, Marcotte N, Lacombe L, et al.: Salvage therapy for BCG failure with intravesical sequential gemcitabine and docetaxel in patients with recurrent NMIBC. Can Urol Assoc J 2024; 18: 33\u201340","DOI":"10.5489\/cuaj.8341"},{"key":"10.3238\/arztebl.m2025.0014_ref20","doi-asserted-by":"crossref","unstructured":"Boorjian SA, Alemozaffar M, Konety BR, et al.: Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol 2021; 22: 107\u201317","DOI":"10.1016\/S1470-2045(20)30540-4"},{"key":"10.3238\/arztebl.m2025.0014_ref21","doi-asserted-by":"crossref","unstructured":"Balar AV, Kamat AM, Kulkarni GS, et al.: Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol 2021; 22: 919\u201330","DOI":"10.1016\/S1470-2045(21)00147-9"},{"key":"10.3238\/arztebl.m2025.0014_ref22","doi-asserted-by":"crossref","unstructured":"Necchi A, Roumigui\u00e9 M, Kamat AM, et al.: Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): a single-arm, multicentre, phase 2 trial. Lancet Oncol 2024; 25: 720\u201330","DOI":"10.1016\/S1470-2045(24)00178-5"},{"key":"10.3238\/arztebl.m2025.0014_ref23","doi-asserted-by":"crossref","unstructured":"Solsona E, Iborra I, Collado A, Rubio-Briones J, Casanova J, Calatrava A: Feasibility of radical transurethral resection as monotherapy for selected patients with muscle invasive bladder cancer. J Urol 2010; 184: 475\u201380","DOI":"10.1016\/j.juro.2010.04.008"},{"key":"10.3238\/arztebl.m2025.0014_ref24","doi-asserted-by":"crossref","unstructured":"Mazza P, Moran GW, Li G, et al.: Conservative management following complete clinical response to neoadjuvant chemotherapy of muscle invasive bladder cancer: contemporary outcomes of a multi-institutional cohort study. J Urol 2018; 200: 1005\u201313","DOI":"10.1016\/j.juro.2018.05.078"},{"key":"10.3238\/arztebl.m2025.0014_ref25","doi-asserted-by":"crossref","unstructured":"Herr HW: Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol 2008; 54: 126\u201332","DOI":"10.1016\/j.eururo.2007.12.031"},{"key":"10.3238\/arztebl.m2025.0014_ref26","doi-asserted-by":"crossref","unstructured":"Ham WS, Park JS, Jang WS, Kim J: Role of maximal transurethral resection preceding partial cystectomy for muscle-invasive bladder cancer. Ann Surg Oncol 2024; 31: 1384\u201392","DOI":"10.1245\/s10434-023-14449-5"},{"key":"10.3238\/arztebl.m2025.0014_ref27","doi-asserted-by":"crossref","unstructured":"Basile G, Bandini M, Gibb EA, et al.: Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01\u00a0trial. Clin Cancer Res 2022; 28: 5107\u201314","DOI":"10.1158\/1078-0432.CCR-22-2158"},{"key":"10.3238\/arztebl.m2025.0014_ref28","doi-asserted-by":"crossref","unstructured":"Szabados B, Kockx M, Assaf ZJ, et al.: Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder. Eur Urol 2022; 82: 212\u201322","DOI":"10.1016\/j.eururo.2022.04.013"},{"key":"10.3238\/arztebl.m2025.0014_ref29","doi-asserted-by":"crossref","unstructured":"Li R, Nocera L, Rose KM, et al.: Comparative effectiveness of neoadjuvant pembrolizumab versus cisplatin-based chemotherapy or upfront radical cystectomy in patients with muscle-invasive urothelial bladder cancer. Eur Urol Oncol 2024; 7: 614\u201324","DOI":"10.1016\/j.euo.2023.12.008"},{"key":"10.3238\/arztebl.m2025.0014_ref30","doi-asserted-by":"crossref","unstructured":"Powles T, Catto JWF, Galsky MD, et al.: Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer. N Engl J Med 2024; 391: 1773\u201386","DOI":"10.1056\/NEJMoa2408154"},{"key":"10.3238\/arztebl.m2025.0014_ref31","doi-asserted-by":"crossref","unstructured":"Galsky MD, Daneshmand S, Izadmehr S, et al.: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial. Nat Med 2023; 29: 2825\u201334","DOI":"10.1038\/s41591-023-02568-1"},{"key":"10.3238\/arztebl.m2025.0014_ref32","doi-asserted-by":"crossref","unstructured":"Kassouf W, Swanson D, Kamat AM, et al.: Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience. J Urol 2006; 175: 2058\u201362","DOI":"10.1016\/S0022-5347(06)00322-3"},{"key":"10.3238\/arztebl.m2025.0014_ref33","doi-asserted-by":"crossref","unstructured":"Holzbeierlein JM, Lopez-Corona E, Bochner BH, et al.: Partial cystectomy: a contemporary review of the Memorial Sloan-Kettering Cancer Center experience and recommendations for patient selection. J Urol 2004; 172: 878\u201381","DOI":"10.1097\/01.ju.0000135530.59860.7d"},{"key":"10.3238\/arztebl.m2025.0014_ref34","doi-asserted-by":"crossref","unstructured":"Capitanio U, Isbarn H, Shariat SF, et al.: Partial cystectomy does not undermine cancer control in appropriately selected patients with urothelial carcinoma of the bladder: a population-based matched analysist. Urology 2009; 74: 858\u201364","DOI":"10.1016\/j.urology.2009.03.052"},{"key":"10.3238\/arztebl.m2025.0014_ref35","doi-asserted-by":"crossref","unstructured":"Knoedler JJ, Boorjian SA, Kim SP, et al.: Does partial cystectomy compromise oncologic outcomes for patients with bladder cancer compared to radical cystectomy? A matched case-control analysis. J Urol 2012; 188: 1115\u20139","DOI":"10.1016\/j.juro.2012.06.029"},{"key":"10.3238\/arztebl.m2025.0014_ref36","doi-asserted-by":"crossref","unstructured":"Zlotta AR, Ballas LK, Niemierko A, et al.: Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis. Lancet Oncol 2023; 24: 669\u201381","DOI":"10.1016\/S1470-2045(23)00170-5"},{"key":"10.3238\/arztebl.m2025.0014_ref37","doi-asserted-by":"crossref","unstructured":"Ditonno F, Veccia A, Montanaro F, et al.: Trimodal therapy vs radical cystectomy in patients with muscle-invasive bladder cancer: a systematic review and meta-analysis of comparative studies. BJU Int 2024; 134: 684\u201395","DOI":"10.1111\/bju.16366"},{"key":"10.3238\/arztebl.m2025.0014_ref38","doi-asserted-by":"crossref","unstructured":"Kijima T, Tanaka H, Koga F, et al.: Selective tetramodal bladder-preservation therapy, incorporating induction chemoradiotherapy and consolidative partial cystectomy with pelvic lymph node dissection for muscle-invasive bladder cancer: oncological and functional outcomes of 107 patients. BJU Int 2019; 124: 242\u201350","DOI":"10.1111\/bju.14736"},{"key":"10.3238\/arztebl.m2025.0014_ref39","doi-asserted-by":"crossref","unstructured":"International Collaboration of Trialists: International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 2011; 29: 2171\u20137","DOI":"10.1200\/JCO.2010.32.3139"},{"key":"10.3238\/arztebl.m2025.0014_ref40","doi-asserted-by":"crossref","unstructured":"Hall E, Hussain SA, Porta N, et al.: Chemoradiotherapy in muscle-invasive bladder cancer: 10-yr follow-up of the phase 3 randomised controlled BC2001\u00a0trial. Eur Urol 2022; 82: 273\u20139","DOI":"10.1016\/j.eururo.2022.04.017"},{"key":"10.3238\/arztebl.m2025.0014_ref41","doi-asserted-by":"crossref","unstructured":"Comp\u00e9rat E, Varinot J, Moroch J, Eymerit-Morin C, Brimo F: A practical guide to bladder cancer pathology. Nat Rev Urol 2018; 15: 143\u201354","DOI":"10.1038\/nrurol.2018.2"},{"key":"10.3238\/arztebl.m2025.0014_ref42","doi-asserted-by":"crossref","unstructured":"Shelley MD, Kynaston H, Court J, et al.: A systemic review of intravesical bacillus Calmette-Gu\u00e9rin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int 2001; 88: 209\u201316","DOI":"10.1046\/j.1464-410x.2001.02306.x"},{"key":"10.3238\/arztebl.m2025.0014_ref43","doi-asserted-by":"crossref","unstructured":"van der Meijden AP, Sylvester RJ, Oosterlinck W, Hoeltl W, Bono AV; EORTC Genito-Urinary Tract Cancer Group: Maintenance bacillus Calmette-Gu\u00e9rin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group phase III Trial. Eur Urol 2003; 44: 429\u201334","DOI":"10.1016\/S0302-2838(03)00357-9"},{"key":"10.3238\/arztebl.m2025.0014_ref44","doi-asserted-by":"crossref","unstructured":"Martini A, Sfakianos JP, Renstr\u00f6m-Koskela L, et al.: The natural history of untreated muscle-invasive bladder cancer. BJU Int 2020; 125: 270\u20135","DOI":"10.1111\/bju.14872"},{"key":"10.3238\/arztebl.m2025.0014_ref45","doi-asserted-by":"crossref","unstructured":"Vlaming M, Kiemeney LALM, van der Heijden AG: Survival after radical cystectomy: progressive versus de novo muscle invasive bladder cancer. Cancer Treat Res Commun 2020; 25: 100264","DOI":"10.1016\/j.ctarc.2020.100264"},{"key":"10.3238\/arztebl.m2025.0014_ref46","doi-asserted-by":"crossref","unstructured":"Bahlburg H, Reicherz A, Reike M, et al.: A prospective evaluation of quality of life, psychosocial distress, and functional outcomes two years after radical cystectomy and urinary diversion in 842 German bladder cancer patients. J Cancer Surviv 2024. doi: 10.1007\/s11764\u2013024\u201301535\u20130. Online ahead of print","DOI":"10.1007\/s11764-024-01535-0"},{"key":"10.3238\/arztebl.m2025.0014_ref47","doi-asserted-by":"crossref","unstructured":"Verghote F, Van Praet C, Berquin C, et al.: Radical cystectomy or trimodality therapy for muscle-invasive bladder cancer: a qualitative study exploring patient priorities and counselling needs when making a treatment choice. BMC Cancer 2024; 24: 160","DOI":"10.1186\/s12885-024-11927-1"},{"key":"10.3238\/arztebl.m2025.0014_ref48","doi-asserted-by":"crossref","unstructured":"Winoker JS, Liaw CW, Galsky MD, Wiklund P, Mehrazin R: Clinical complete response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: a call for standardized assessments and definitions. Eur Urol Focus 2020; 6: 627\u20139","DOI":"10.1016\/j.euf.2019.08.009"},{"key":"10.3238\/arztebl.m2025.0014_ref49","doi-asserted-by":"crossref","unstructured":"Pfister C, Gravis G, Fl\u00e9chon A, et al.: Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: results of the GETUG-AFU V05 VESPER trial. J Clin Oncol 2022; 40: 2013\u201322","DOI":"10.1200\/JCO.21.02051"},{"key":"10.3238\/arztebl.m2025.0014_ref50","doi-asserted-by":"crossref","unstructured":"Serrano M, Mu\u00f1oz-Unceta N, Alonso LA, et al.: Neoadjuvant chemotherapy with dose-dense MVAC in muscle-invasive bladder cancer: a tertiary center experience. Clin Transl Oncol 2024; 26: 549\u201353","DOI":"10.1007\/s12094-023-03277-4"},{"key":"10.3238\/arztebl.m2025.0014_ref51","doi-asserted-by":"crossref","unstructured":"Li R, Nocera L, Rose KM, et al.: Comparative effectiveness of neoadjuvant pembrolizumab versus cisplatin-based chemotherapy or upfront radical cystectomy in patients with muscle-invasive urothelial bladder cancer. Eur Urol Oncol 2024; 7: 614\u201324","DOI":"10.1016\/j.euo.2023.12.008"},{"key":"10.3238\/arztebl.m2025.0014_ref52","doi-asserted-by":"crossref","unstructured":"Vilaseca A, Jayram G, Raventos C, et al.: LBA104 first safety and efficacy results of the TAR-210 erdafitinib (erda) intravesical delivery system in patients (pts) with non-muscle-invasive bladder cancer (NMBIC) with select FGFR alterations (alt). Ann Oncol 2023; 34: S1343","DOI":"10.1016\/j.annonc.2023.10.110"},{"key":"10.3238\/arztebl.m2025.0014_ref53","doi-asserted-by":"crossref","unstructured":"Kural S, Pathak AK, Singh S, et al.: Prospective assessment of VI-RADS with muscle invasion in urinary bladder cancer and its implication on re-resection\/restaging TURBT patients. Ann Surg Oncol 2025; 32: 609\u201318","DOI":"10.1245\/s10434-024-16424-0"},{"key":"10.3238\/arztebl.m2025.0014_ref54","doi-asserted-by":"crossref","unstructured":"Jaromin M, Konecki T, Kutwin P: Revolutionizing treatment: breakthrough approaches for BCG-unresponsive non-muscle-invasive bladder cancer. Cancers (Basel) 2024; 16: 1366","DOI":"10.3390\/cancers16071366"},{"key":"10.3238\/arztebl.m2025.0014_ref55","doi-asserted-by":"crossref","unstructured":"Hannouneh ZA, Hijazi A, Alsaleem AA, et al.: Novel immunotherapeutic options for BCG-unresponsive high-risk non-muscle-invasive bladder cancer. Cancer Med 2023; 12: 21944\u201368","DOI":"10.1002\/cam4.6768"},{"key":"10.3238\/arztebl.m2025.0014_ref56","doi-asserted-by":"crossref","unstructured":"Huang S, Huang Y, Li C, et al.: Efficacy and safety of neoadjuvant PD-1\u00a0inhibitors or PD-L1\u00a0inhibitors for muscle invasive bladder cancer: a systematic review and meta-analysis. Front Immunol 2024; 14: 1332213.","DOI":"10.3389\/fimmu.2023.1332213"},{"key":"10.3238\/arztebl.m2025.0014_ref57","doi-asserted-by":"crossref","unstructured":"Krishnatry R, Maitre P, Kumar A, et al.: Utilising alternative cystoscopic schedules to minimize cost and patient burden after trimodality therapy for muscle-invasive bladder cancer. Cancer Med 2023; 12: 11305\u201314","DOI":"10.1002\/cam4.5840"},{"key":"10.3238\/arztebl.m2025.0014_ref58","doi-asserted-by":"crossref","unstructured":"Joshi M, Tuanquin L, Zhu J, et al.: Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15\u2013023. J Immunother Cancer 2023; 11: e006551","DOI":"10.1136\/jitc-2022-006551"},{"key":"10.3238\/arztebl.m2025.0014_ref59","doi-asserted-by":"crossref","unstructured":"Coppin CM, Gospodarowicz MK, James K, et al.: Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996; 14: 2901\u20137","DOI":"10.1200\/JCO.1996.14.11.2901"},{"key":"10.3238\/arztebl.m2025.0014_ref60","doi-asserted-by":"crossref","unstructured":"Hoskin PJ, Rojas AM, Bentzen SM, Saunders MI: Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. J Clin Oncol 2010; 28: 4912\u20138","DOI":"10.1200\/JCO.2010.28.4950"},{"key":"10.3238\/arztebl.m2025.0014_ref61","doi-asserted-by":"crossref","unstructured":"Coen JJ, Zhang P, Saylor PJ, et al.: Bladder preservation with twice-a-day radiation plus fluorouracil\/cisplatin or once daily radiation plus gemcitabine for muscle-invasive bladder cancer: NRG\/RTOG 0712. A randomized phase II trial. J Clin Oncol 2019; 37: 44\u201351","DOI":"10.1200\/JCO.18.00537"},{"key":"10.3238\/arztebl.m2025.0014_ref62","doi-asserted-by":"crossref","unstructured":"Caffo O, Thompson C, De Santis M, et al.: Concurrent gemcitabine and radiotherapy for the treatment of muscle-invasive bladder cancer: a pooled individual data analysis of eight phase I-II trials. Radiother Oncol 2016; 121: 193\u20138","DOI":"10.1016\/j.radonc.2016.09.006"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2025.0014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T07:59:35Z","timestamp":1744358375000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2025.0014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,18]]},"references-count":62,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2025.0014","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,18]]}}}